Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

BACKGROUND: The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) brings remarkable benefits for the survival of patients with advanced NSCLC harboring EGFR mutations. Unfortunately, acquired resistance seems to be inevitable and limits the application of EGFR-TKIs in cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Zhenzhen, Wang, Kai, Wang, Xiniao, Jia, Zhirong, Yang, Yuqi, Duan, Yalei, Huang, Lianzhan, Wu, Zhuo-Xun, Zhang, Jian-ye, Ding, Xuansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932110/
https://www.ncbi.nlm.nih.gov/pubmed/35303882
http://dx.doi.org/10.1186/s12943-022-01547-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932110/
https://www.ncbi.nlm.nih.gov/pubmed/35303882
http://dx.doi.org/10.1186/s12943-022-01547-3

Ejemplares similares